<DOC>
	<DOCNO>NCT02279420</DOCNO>
	<brief_summary>This multicenter , un-blinded , open label , pivotal supplemental study G130163 intend evaluate safety efficacy treat previous sham subject Essential pivotal trial ( IDE # G130163 ) active treatment ( placement g-Cath EZ suture anchor along diet exercise ) . Compliant sham subject ( attended primary IDE follow-up visit AND continue meet eligibility criterion describe protocol ) offer active treatment 12 month unblinding visit Essential pivotal trial .</brief_summary>
	<brief_title>ESSENTIAL Trial™ Sham Cross-over</brief_title>
	<detailed_description>This multicenter , un-blinded , open label , pivotal supplemental study G130163 intend evaluate safety efficacy treat previous sham subject Essential pivotal trial ( IDE # G130163 ) active treatment ( placement g-Cath EZ suture anchor along diet exercise ) . Compliant sham subject ( attended primary IDE follow-up visit AND continue meet eligibility criterion describe protocol ) offer active treatment 12 month unblinding visit Essential pivotal trial . This supplemental study consist 8 week screen period subject 's unblinding visit , enrollment ( active treatment ) day , 12-month follow-up period . All sham subject Essential Trial ( total quantity one hundred eleven ( 111 ) subject ) plan enrollment , total quantity sham subject provide active treatment depend number subject compliant . The active treatment provide original investigator subject investigational center ( one original 11 ) use Essential trial . Collection data accomplish utilizing independent nutritionists/clinical research nurse administer diet/exercise plan collect weight loss efficacy assessment . Efficacy assessment also include change select co-morbidities , quality life assessment , change hunger satiety , among others . Safety assessment include subject investigator report adverse event , physician follow-up assessment , blood pressure measurement .</detailed_description>
	<criteria>1 . Provide write informed consent . 2 . Potential subject sham participant Essential pivotal trial 3 . Potential subject agree compliant study document history compliance pivotal study . 4 . Subjects age 2361 year . 5 . If female , either postmenopausal , surgically sterile agree practice birth control year study negative serum HCG screening/baseline . 6 . Have Body Mass Index ( BMI ) ≥30 &lt; 35 least one nonsevere comorbid obesity relate condition BMI ≥ 35 without nonsevere obesity relate comorbid condition , severe comorbid condition define severe symptom cause severe discomfort , performance daily activity compromise , and/or condition entirely control prescription drug therapy ( See Section 14 ) 7 . Absence current severe systemic disease ( include , limited : coronary artery disease , chronic obstructive pulmonary disease , congestive heart failure , cancer , chronic renal disease ) 8 . Agrees undergo additional weight loss interventional procedure liposuction 12 month follow study enrollment . 9 . Agrees utilize prescription counter weight loss medication OR suppress appetite/induce weight loss 12 month follow study enrollment ( include stimulant medication ) . 10 . Be willing cooperate postoperative dietary recommendation assessment test . 11 . Residing within reasonable distance Investigator 's treating office ( ~50 mile ) able willing travel Investigator 's office complete routine followup visit . 1 . History ( intraoperative evidence ) prior bariatric , gastric esophageal surgery . 2 . Esophageal stricture anatomy and/or condition could preclude passage endolumenal instrument procedure execution . 3 . Severe gastroesophageal reflux disease ( GERD ) , define symptom cause subject severe discomfort , compromise performance daily activity , and/or condition entirely control drug therapy . 4 . Large hiatal hernia ( &gt; 3 cm ) history determine preenrollment endoscopy . 5 . Pancreatic insufficiency/disease . 6 . History gastroparesis symptom would suggestive gastroparesis . 7 . Pregnancy plan pregnancy next 12 month . 8 . Immunosuppressive medication systemic steroid ( i.e. , oral prednisone ) within 1 month Visit 1 . Intranasal/inhaled steroid acceptable . 9 . History inflammatory disease GI tract ; coagulation disorder ; hepatic insufficiency cirrhosis 10 . History present use insulin insulin derivative treatment diabetes 11 . Type II Diabetes Mellitus ( define HgbA1c &gt; 6.5 % ) great 11 year time enrollment 12 . If smoker , plan quit smoke year enrollment 13 . Portal hypertension and/or varix . 14 . Significant abnormality identify Visit 2 ( enrollment visit ) endoscopy reveal large hiatal hernia , gastric/duodenal ulcer , gastric erosion , gastric outlet obstruction stenosis , etc . 15 . Patient history drug alcohol abuse positive screening drug abuse . 16 . Present past history psychosis , bipolar disease , obsessive compulsive disorder preenrollment history medical /psychological assessment 17 . Nonambulatory significant impairment mobility . 18 . Known hormonal genetic cause obesity include untreated hypothyroidism ( TSH &gt; 5.0 U/ml ) . 19 . Participating another clinical study except Essential Study . 20 . Subjects personal history allergic/anaphylactic reaction include hypersensitivity drug material utilize study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>